Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress
Triumvira Immunologics ("Triumvira"), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients
France General United States Kostenloser Wertpapierhandel Stephanie Carrington Benjaminl Schlechter Triumvira Immunologics
Source: finanznachrichten.de